LT2704711T - Fk506 panaudojimas plaučių arterinei hipertenzijai gydyti - Google Patents

Fk506 panaudojimas plaučių arterinei hipertenzijai gydyti

Info

Publication number
LT2704711T
LT2704711T LTEP12779354.5T LT12779354T LT2704711T LT 2704711 T LT2704711 T LT 2704711T LT 12779354 T LT12779354 T LT 12779354T LT 2704711 T LT2704711 T LT 2704711T
Authority
LT
Lithuania
Prior art keywords
treatment
arterial hypertension
pulmonary arterial
pulmonary
hypertension
Prior art date
Application number
LTEP12779354.5T
Other languages
English (en)
Lithuanian (lt)
Inventor
Edda SPIEKERKOETTER
Marlene Rabinovitch
Philip Beachy
David Solow-Cordero
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of LT2704711T publication Critical patent/LT2704711T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LTEP12779354.5T 2011-05-02 2012-04-30 Fk506 panaudojimas plaučių arterinei hipertenzijai gydyti LT2704711T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161481317P 2011-05-02 2011-05-02
PCT/US2012/035793 WO2012151153A1 (en) 2011-05-02 2012-04-30 Use of fk506 for the treatment of pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
LT2704711T true LT2704711T (lt) 2021-04-26

Family

ID=47108011

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12779354.5T LT2704711T (lt) 2011-05-02 2012-04-30 Fk506 panaudojimas plaučių arterinei hipertenzijai gydyti

Country Status (19)

Country Link
US (6) US9474745B2 (enExample)
EP (3) EP2704711B1 (enExample)
JP (1) JP6177765B2 (enExample)
AU (2) AU2012250974B9 (enExample)
CA (1) CA2834368C (enExample)
CY (1) CY1123900T1 (enExample)
DK (2) DK3821891T3 (enExample)
ES (2) ES2856173T3 (enExample)
FI (1) FI3821891T3 (enExample)
HR (1) HRP20210245T1 (enExample)
HU (1) HUE053229T2 (enExample)
LT (1) LT2704711T (enExample)
PL (1) PL2704711T3 (enExample)
PT (2) PT3821891T (enExample)
RS (1) RS61480B1 (enExample)
SI (1) SI2704711T1 (enExample)
SM (1) SMT202100085T1 (enExample)
WO (1) WO2012151153A1 (enExample)
ZA (1) ZA201307905B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2704711T3 (pl) 2011-05-02 2021-07-05 The Board Of Trustees Of The Leland Stanford Junior University Zastosowanie fk506 w leczeniu tętniczego nadciśnienia płucnego
KR102569428B1 (ko) * 2015-01-13 2023-08-21 비버스 인크. 폐 고혈압을 위한 병용 요법
EP3294294A4 (en) * 2015-05-08 2019-01-02 Vivus, Inc. Compositions and methods for the treatment or prevention of pulmonary hypertension
CN108070566A (zh) * 2015-08-05 2018-05-25 中国医学科学院基础医学研究所 肺动脉高压治疗药物的干细胞筛选模型及应用
ES2683921B1 (es) * 2017-03-28 2019-04-22 Univ Vigo Método para la determinación del pronóstico en sujetos diagnosticados con hipertensión arterial pulmonar
EP3624821A4 (en) 2017-05-19 2021-01-20 The Board of Trustees of the Leland Stanford Junior University ENZASTAURIN AND FRAGILE HISTIDINTRIAD (FHIT) - ENHANCING AGENTS FOR TREATMENT OF PULMONAL HYPERTENSION
US12440479B2 (en) 2018-03-28 2025-10-14 Georg-August-Universitaet Goettingen, Stiftung Oeffentlichen Rechts, Universitaetsmedizin Prevention or treatment of chronic organ injury

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
CN101443004B (zh) 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
FR2936060B1 (fr) 2008-09-17 2010-11-19 Assist Publ Hopitaux De Paris Procede de diagnostic d'une sclerodermie systemique ou d'une hypertension arterielle pulmonaire.
JP2012506434A (ja) * 2008-10-22 2012-03-15 サム アマー アンド カンパニー インコーポレーテッド 肺動脈高血圧症の治療方法
PL2704711T3 (pl) 2011-05-02 2021-07-05 The Board Of Trustees Of The Leland Stanford Junior University Zastosowanie fk506 w leczeniu tętniczego nadciśnienia płucnego

Also Published As

Publication number Publication date
US20230404982A1 (en) 2023-12-21
AU2017210583A1 (en) 2017-08-24
FI3821891T3 (fi) 2023-08-24
US12521379B2 (en) 2026-01-13
EP2704711B1 (en) 2020-12-02
HRP20210245T1 (hr) 2021-04-02
US20170007585A1 (en) 2017-01-12
ES2856173T3 (es) 2021-09-27
WO2012151153A1 (en) 2012-11-08
US20140135358A1 (en) 2014-05-15
HUE053229T2 (hu) 2021-06-28
EP2704711A4 (en) 2014-11-19
US20220184042A1 (en) 2022-06-16
AU2017210583B2 (en) 2019-02-07
JP6177765B2 (ja) 2017-08-09
SI2704711T1 (sl) 2021-04-30
DK2704711T3 (da) 2021-02-22
EP4279130A3 (en) 2024-02-21
EP3821891B1 (en) 2023-06-07
US20190091208A1 (en) 2019-03-28
DK3821891T3 (da) 2023-09-04
AU2012250974A1 (en) 2013-11-14
AU2012250974B9 (en) 2017-05-18
US20180185340A1 (en) 2018-07-05
US9474745B2 (en) 2016-10-25
CA2834368A1 (en) 2012-11-08
JP2014513121A (ja) 2014-05-29
EP2704711A1 (en) 2014-03-12
ZA201307905B (en) 2015-05-27
CY1123900T1 (el) 2022-05-27
EP3821891A1 (en) 2021-05-19
EP4279130A2 (en) 2023-11-22
AU2012250974B2 (en) 2017-05-04
CA2834368C (en) 2020-02-18
PT2704711T (pt) 2021-03-02
PT3821891T (pt) 2023-08-31
RS61480B1 (sr) 2021-03-31
SMT202100085T1 (it) 2021-05-07
ES2954905T3 (es) 2023-11-27
PL2704711T3 (pl) 2021-07-05

Similar Documents

Publication Publication Date Title
PL2544682T3 (pl) Fitokannabinoidy w leczeniu glejaka
IL231228A0 (en) Bicyclic heterocycle derivatives for the treatmen t of pulmonary arterial hypertension
IL235512B (en) Phenylbenzamide derivatives for use in treating diseases mediated by aquaporin
DK2539015T3 (da) Nethindeprotese
DK2734128T3 (da) Kirurgisk hentningsindretning med halvstift udtrækkelig og sammenklappelig kurv
DK2734126T3 (da) Medicinske anordninger med aftagelige drejelige kæber
DK3730136T3 (da) Anvendelse af ferricitrat til behandlingen af patienter med kronisk nyresygdom
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
IL237021B (en) Pharmaceutical composition for treatment of pulmonary arterial hypertension with mesenchymal stem cells
PL2717692T3 (pl) Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych
ME02952B (me) Wnt antagonisti i metode tretiranja
HRP20171579T8 (hr) Antigljivična sredstva i njihova upotreba
EP2793912A4 (en) ORGANIC WITH DECELLULARIZED AND REASSEMBLED PLAZENTAL VASCULAR SCAFFOLDING
EP2672941A4 (en) DISPOSABLE CLOTHING ARTICLE
EP2774585A4 (en) Stent
CO6870004A2 (es) Métodos de modulación de un microarn en el tratamiento de la hipertensión arterial pulmonar
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej
BR112014009789A2 (pt) cisteamina no tratamento da doença fibrótica
PL2704711T3 (pl) Zastosowanie fk506 w leczeniu tętniczego nadciśnienia płucnego
IL229537A0 (en) Hypertension and hyperuricemia
DK2590565T3 (da) Blodprøvetagning
EP3396052C0 (en) OPTIMIZED DISHWASHER AND ITS USE
LT2872145T (lt) Sujungti benzazepinai tureto sindromui gydyti
HRP20180011T1 (hr) Spojevi za uporabu u liječenju filariaza
LT2702033T (lt) 3-karboksi-n-etil-n,n-dimetilpropan-1-amino druskos panaudojimas kardiovaskuliarinių ligų gydyme